MBX Biosciences, Inc. MBX 深 沪
等待开盘 05-20 09:30:00 美东时间
30.39
-0.590
-1.90%
华盛通- 最 高31.16
- 今 开30.65
- 成交量 61.01万股
- 最 低 29.60
- 昨 收 30.98
- 总市值 14.46亿
- 52周最高 45.85
- 市盈率 静 --
- 换手率 1.28%
- 52周最低 9.43
- 委 比 -95.57%
- 总股本 4759.75万
- 历史最高 45.85
- 量 比 0.72
- 振 幅 5.04%
- 历史最低 4.8069
- 每 手 1
- 风险率 10.03%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Scheduled For May 14, 2026
Companies Reporting Before The Bell • Urban One (NASDAQ:UONEK) is expected to r...
05-14 19:11
美股大行评级 | 富国银行上调英伟达目标价从265美元升至315美元；Alamar、AEVEX获多家大行首予“买入”评级
今日重点评级关注：Needham：维持Artiva Biotherapeutics"买入"评级，目标价从18美元升至41美元；HC Wainwright & Co.：维持SAB Biotherapeutics"买入"评级，目标价从7美元升至10美元
05-13 11:46
美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元
05-12 12:36
MBX Biosciences Announces Multiple Updates On Obesity Portfolio; Preliminary Blinded Phase 1 Data For MBX 4291 Show Pharmacokinetic Profile Supporting Potential For Once-Monthly Dosing And Competitive Weight Loss In First MAD Cohort
Preliminary blinded data from ongoing Phase 1 trial demonstrated mean weight loss of 7% (range 0-16%) at 8 weeks in first MAD Part B cohort (n=8, including 2 placebo)MBX 4291 generally well tolerated, only one event of
05-11 19:06
美股夜盘 | Fundrise Innovation Fund, LLC涨16.13%，奇景光电涨11.30%
Fundrise Innovation Fund, LLC涨16.13%；奇景光电涨11.30%；Inhibrx Biosciences, Inc.涨11.28%
05-11 13:01
美股夜盘 | Rackspace Technology, Inc.涨16.39%，Fundrise Innovation Fund, LLC涨15.71%
Rackspace Technology, Inc.涨16.39%；Fundrise Innovation Fund, LLC涨15.71%；奇景光电涨14.45%
05-11 10:01
MBX Biosciences Q1 EPS $(0.51) Beats $(0.61) Estimate
MBX Biosciences (NASDAQ:MBX) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.61) by 16.39 percent. This is a 28.17 percent increase over losses of $(0.71) per share from
05-07 20:13
MBX Biosciences Q4 EPS $(0.49) Beats $(0.68) Estimate
MBX Biosciences (NASDAQ:MBX) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.68) by 27.84 percent. This is a 4.26 percent decrease over losses of $(0.47) per share from the
03-12 20:14
MBX Biosciences Announces End-of-Phase 2 FDA Meeting Results and Provides Phase 3 Development Plan For Canvuparatide
Based on feedback from the FDA, MBX plans to advance once-weekly canvuparatide into a Phase 3 trial in the third quarter of 2026.
03-09 20:09
Earnings Scheduled For February 12, 2026
Companies Reporting Before The Bell • Ambev (NYSE:ABEV) is estimated to report ...
02-12 19:11
